Literature DB >> 17543821

Understanding how opioids contribute to reward and analgesia.

Howard L Fields1.   

Abstract

Opioids acting at the mu opioid (MOP) receptor produce powerful analgesia. They also produce an intensely rewarding effect that can lead to addiction. The analgesic effect of MOP receptor agonists derives from a direct inhibitory effect on pain transmission at the spinal-cord level and through activation of a descending pain-modulatory pathway. The rewarding effect of MOP agonists is the result of their actions in the mesostriatal dopamine pathway classically associated with both natural and drug rewards. Both the analgesic and rewarding effect of MOP agonists are best understood in the context of decision making under conditions of conflict. Pain is one of many competing motivational states, and endogenous opioids suppress responses to noxious stimuli in the presence of conflicting motivations, such as hunger or a threatening predator. When a food reward is available, MOP agonists microinjected into the mesostriatal circuit promote its consumption, while concomitantly suppressing responses to noxious stimulation. The mesostriatal "reward" circuit, thus, appears to perform a function critical to decision making and can either amplify or suppress responses to noxious stimuli.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17543821     DOI: 10.1016/j.rapm.2007.01.001

Source DB:  PubMed          Journal:  Reg Anesth Pain Med        ISSN: 1098-7339            Impact factor:   6.288


  64 in total

1.  Screening for addictive disorders within a workers' compensation clinic: an exploratory study.

Authors:  Iman Parhami; Mark Hyman; Aaron Siani; Stephanie Lin; Michael Collard; Johnny Garcia; Laurie Casaus; John Tsuang; Timothy W Fong
Journal:  Subst Use Misuse       Date:  2011-11-08       Impact factor: 2.164

Review 2.  Pain and suicidality: insights from reward and addiction neuroscience.

Authors:  Igor Elman; David Borsook; Nora D Volkow
Journal:  Prog Neurobiol       Date:  2013-07-01       Impact factor: 11.685

Review 3.  Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.

Authors:  Aswini Kumar Giri; Victor J Hruby
Journal:  Expert Opin Investig Drugs       Date:  2013-12-13       Impact factor: 6.206

4.  Calcium-permeable AMPA receptors in the nucleus accumbens regulate depression-like behaviors in the chronic neuropathic pain state.

Authors:  Yossef Goffer; Duo Xu; Sarah E Eberle; James D'amour; Michelle Lee; David Tukey; Robert C Froemke; Edward B Ziff; Jing Wang
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

Review 5.  [Chronic pain : Perception, reward and neural processing].

Authors:  S Becker; M Diers
Journal:  Schmerz       Date:  2016-10       Impact factor: 1.107

Review 6.  Evaluation of reward from pain relief.

Authors:  Edita Navratilova; Jennifer Yanhua Xie; Tamara King; Frank Porreca
Journal:  Ann N Y Acad Sci       Date:  2013-03-15       Impact factor: 5.691

7.  Preemptive Stimulation of AgRP Neurons in Fed Mice Enables Conditioned Food Seeking under Threat.

Authors:  Nick Jikomes; Rohan N Ramesh; Yael Mandelblat-Cerf; Mark L Andermann
Journal:  Curr Biol       Date:  2016-08-25       Impact factor: 10.834

8.  Neuroanatomical distribution of μ-opioid receptor mRNA and binding in monogamous prairie voles (Microtus ochrogaster) and non-monogamous meadow voles (Microtus pennsylvanicus).

Authors:  K Inoue; J P Burkett; L J Young
Journal:  Neuroscience       Date:  2013-03-26       Impact factor: 3.590

9.  AMPAkines Target the Nucleus Accumbens to Relieve Postoperative Pain.

Authors:  Chen Su; Hau Yeuh Lin; Runtao Yang; Duo Xu; Michelle Lee; Natalie Pawlak; Monica Norcini; Alexandra Sideris; Esperanza Recio-Pinto; Dong Huang; Jing Wang
Journal:  Anesthesiology       Date:  2016-11       Impact factor: 7.892

10.  Cocaine drives aversive conditioning via delayed activation of dopamine-responsive habenular and midbrain pathways.

Authors:  Thomas C Jhou; Cameron H Good; Courtney S Rowley; Sheng-Ping Xu; Huikun Wang; Nathan W Burnham; Alexander F Hoffman; Carl R Lupica; Satoshi Ikemoto
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.